OPKO Health to Participate in the Barclays Global Healthcare Conference
March 14 2017 - 8:00AM
OPKO Health, Inc. (NASDAQ:OPK) today announces that senior
management will participate at the Barclays Global Healthcare
Conference taking place March 14-16, 2017 at Loew’s Miami Beach
Hotel. Company management will deliver a corporate overview
on Wednesday, March 15, 2017 at 3:20 p.m. ET.
The Company’s presentation will be webcast live on the OPKO
Investor Relations page of the corporate website at www.opko.com.
To access the live webcast please log onto the OPKO website
approximately fifteen minutes before the presentation to register
and download any necessary audio software. The audio presentation
will be available at this link for a limited time after the live
presentation.
About OPKO HealthOPKO Health is a diversified
healthcare company that seeks to establish industry-leading
positions in large, rapidly growing markets. Our diagnostics
business includes BioReference Laboratories, the nation’s
third-largest clinical laboratory with a core genetic testing
business and a 400-person sales and marketing team to drive growth
and leverage new products, including the 4Kscore® prostate cancer
test and the Claros® 1 in-office immunoassay platform. Our
pharmaceutical business features RAYALDEE, an FDA-approved
treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency (launched in November 2016), VARUBI™ for
chemotherapy-induced nausea and vomiting (oral formulation launched
by partner TESARO and IV formulation pending FDA approval), TT401,
a once or twice weekly oxyntomodulin for type 2 diabetes and
obesity which is a clinically advanced drug candidate among the new
class of GLP-1 glucagon receptor dual agonists (phase 2), and
TT701, an androgen receptor modulator for androgen deficiency
indications (phase 2). Our biologics business includes hGH-CTP, a
once weekly human growth hormone injection (in Phase 3 and
partnered with Pfizer), and a long-acting Factor VIIa drug for
hemophilia (in phase 2a). We also have production and
distribution assets worldwide, multiple strategic investments and
an active business development strategy. More information available
at www.opko.com.
Contacts:
OPKO Health, Inc.David Malina,
305-575-4137dmalina@opko.com
MediaRooney PartnersTerry Rooney,
212-223-0689trooney@rooneyco.com orMarion Janic,
212-223-4017mjanic@rooneyco.com
InvestorsLHAAnne Marie Fields,
212-838-3777afields@lhai.com orBruce Voss,
310-691-7100bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024